What is Citius Oncology, Inc.'s accounts payable?

Citius Oncology, Inc. (CTOR) reported accounts payable of -$1.56M in Q1 2026.

How has Citius Oncology, Inc.'s accounts payable changed year-over-year?

Citius Oncology, Inc.'s accounts payable decreased by 186.8% year-over-year, from $1.8M to -$1.56M.

Over 2 years (2023 to 2025), Citius Oncology, Inc.'s accounts payable has grown at a 182.1% compound annual growth rate (CAGR), from $1.2M to $9.52M.

Merck & Co.MRK

——

ImmunityBio, Inc.IBRX

——

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s accounts payable?: Citius Oncology, Inc. (CTOR) reported accounts payable of -$1.56M in Q1 2026.
How has Citius Oncology, Inc.'s accounts payable changed year-over-year?: Citius Oncology, Inc.'s accounts payable decreased by 186.8% year-over-year, from $1.8M to -$1.56M.
What is the long-term trend for Citius Oncology, Inc.'s accounts payable?: Over 2 years (2023 to 2025), Citius Oncology, Inc.'s accounts payable has grown at a 182.1% compound annual growth rate (CAGR), from $1.2M to $9.52M.